Last reviewed · How we verify
Q10 Coenzyme
Coenzyme Q10 (ubiquinone) functions as an electron carrier in the mitochondrial electron transport chain, facilitating ATP production and acting as a lipophilic antioxidant.
Coenzyme Q10 (ubiquinone) functions as an electron carrier in the mitochondrial electron transport chain, facilitating ATP production and acting as a lipophilic antioxidant. Used for Heart failure and cardiomyopathy, Statin-induced myopathy, Migraine prophylaxis.
At a glance
| Generic name | Q10 Coenzyme |
|---|---|
| Sponsor | Central Hospital, Nancy, France |
| Drug class | Mitochondrial cofactor / Antioxidant |
| Target | Mitochondrial electron transport chain (Complexes I, II, III) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Neurology, General wellness |
| Phase | FDA-approved |
Mechanism of action
Q10 is an endogenous cofactor essential for cellular energy metabolism, particularly in high-energy tissues such as the heart, brain, and skeletal muscle. It accepts and donates electrons in complexes I, II, and III of the electron transport chain, enabling oxidative phosphorylation. Additionally, Q10 scavenges free radicals and regenerates other antioxidants like vitamin E, providing cytoprotective effects.
Approved indications
- Heart failure and cardiomyopathy
- Statin-induced myopathy
- Migraine prophylaxis
- Age-related decline and general antioxidant support
Common side effects
- Gastrointestinal upset (nausea, diarrhea)
- Headache
- Insomnia
- Rash
Key clinical trials
- Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity (PHASE2, PHASE3)
- The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus (PHASE2)
- Alpha Lipoic Acid Plus Coenzyme Q10 Versus Coenzyme Q10 Alone in Asthenozoospermia (NA)
- Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations (PHASE2, PHASE3)
- Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy (NA)
- Coenzyme Q10 for Neuroprotection in Paclitaxel-Induced Neuropathy (PHASE2)
- North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
- Alii Supplement Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Q10 Coenzyme CI brief — competitive landscape report
- Q10 Coenzyme updates RSS · CI watch RSS
- Central Hospital, Nancy, France portfolio CI